In this video interview Dr. Greg Tsongalis addresses sources of pre-analytic variability when processing formalin-fixed, paraffin-embedded (FFPE) samples in a pathology laboratory setting. By 'pre-analytic', he refers to the kinds of kits used for DNA extraction, and other factors that may have a significant impact on the quality of the results. He also discusses his work on clinical assay development for somatic mutation detection using NGS technology.

There are many challenges for pediatric patients struggling with recurrent or refractory cancer but a recent report and accompanying editorial published in the Journal of American Medical Association brings new hope for patients and their families.1 2This three year study also demonstrates how the principles of precision medicine can be successfully applied with existing DNA and RNA sequencing technologies for many patients.

Dr. Condie Carmack has over 30 years of experience in the life sciences and diagnostic industries, having been prior to GenomOncology the Director of Oncology Programs at Vela Diagnostics, developing an NGS-based system for worldwide regulatory approval, and prior to that helped found (as General Manager) the Cancer Genetics Laboratory at Baylor College of Medicine with Dr. Marilyn Li.

In this video interview, SeraCare’s Chief Scientific Officer Dr. Russell Garlick shares some background about SeraCare’s history of manufacturing controls and reference materials for infectious disease diagnostics, and how advances in Precision Medicine reveal a need for similar materials for the fields of oncology and maternal health.